1 ic effects of MET withdrawal with daily i.p. homocystine.

2                  In this assay, S-adenosyl-l-homocystine (AdoHcy/SAH), the by-product of PMT-involved

3 to its low molecular weight disulfide forms (homocystine and homocysteine-cysteine mixed disulfide) b

4 ulfide, cysteine, cystine, homocysteine, and homocystine and the therapeutic agents penicillamine, pe

5 r proliferation in defined medium containing homocystine as the sulfur source.

6 d for homocysteine persulfide synthesis from homocystine by CSE only.

7 ysis confirmed the defect in SAA metabolism: homocystine, cysteine, cystathionine and serine were sig

8                     Only a small fraction of homocystine is formed by an oxidative process in which c

9 teine, because equimolar concentrations of L-homocystine, L-cysteine, and L-methionine had no effect

10                  The latter then reacts with homocystine or homocysteine-cysteine mixed disulfide to

11  internal standard, [3,3,3',3',4,4,4',4'-2H8]homocystine to account for losses associated with the is

12 ith homocysteine-cysteine mixed disulfide or homocystine to form albumin-bound homocysteine.